医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BISTel Showcases Smart Pharma Innovation Award Winner GrandView APM at 2021 Manufacturing Assets and Reliability Conference

2021年05月12日 AM03:54
このエントリーをはてなブックマークに追加


 

SANTA CLARA, Calif.

BISTel, a leading provider of AI asset performance management (APM) solutions for industrial manufacturing, announced today that it will feature its AI based GrandView APM solution at the annual Manufacturing Assets and Reliability in Pharma 2021 Conference.

Winner of the 2020 Pharma Manufacturing Magazine, Smart Pharma Innovation Award, GrandView APM was launched last year to help manufacturers achieve the vision of industry 4.0 by leveraging asset and factory data across the manufacturing ecosystem. The pharmaceutical industry is one of the early adopters of industry 4.0 technologies, deploying digital transformation technologies to help drive continuous improvements at factories worldwide.

“Pharma is making progress in embracing Industry 4.0 and AI based predictive maintenance is one area where they can make a quick and significant impact on the production environment,” said WK Choi, CEO, BISTel. “We are pleased to sponsor the Manufacturing Assets in Pharma conference and to demonstrate our award-winning smart pharma solution.”

BISTel’s innovative asset data centric management approach helps pharma manufactures generate deeper insights at the asset level and across the entire production environment. This approach helps connect, analyze and share knowledge across the ecosystem, using this data to create insights that drive massive continuous improvements for a sector that is constantly looking for ways to improve efficiency and reduce overall production costs.

About GrandView

At this week’s conference, the GrandView™ will show how it provides for continuous monitoring of the health and performance of factory equipment, pumps, motors, fans, and other manufacturing assets and showcase powerful data visualization for all users. Coupled with an asset health index and AI predictive analytics technology, pharma users can generate a RUL (remaining useful life) prediction, pinpointing when assets will fail. Users can also connect the GrandView APM prediction to their plant’s CMMS, EAM or ERP systems, automatically generating a work order to order parts and perform maintenance — thereby minimizing or even eliminating system downtime. In addition, GrandView is scalable and helps transition manufacturers seamlessly and cost effectively from legacy, inefficient scheduled based maintenance to AI predictive based maintenance approaches. This saves manufacturers millions of dollars in maintenance costs alone and extends the life of valuable equipment.

About BISTel

For more than 20 years, BISTel’s AI based, intelligent manufacturing solutions collect and manage data, monitor the health of equipment, optimize process flows, analyze large data, quickly identify root cause failures to mitigate risk, predicting issues before they occur and extending the life of valuable equipment and other assets through industry leading manufacturing AI predictive analytics. BISTel helps customers reduce downtime, improve yield, increase asset utilization, achieving significant production and engineering efficiencies across the factory. Founded in 2000, BISTel has more than 395 employees worldwide. The company is headquartered in South Korea, with US Headquarters in Santa Clara California, and operations throughout China, France, Singapore and Texas. BISTel’s domain expertise in manufacturing AI, includes, auto, flat panel, industrial, petrochemicals, semiconductor as well as automotive, and pharmaceutical manufacturing. For more information visit bistel.com or www.grandview-apm.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511006108/en/

CONTACT

Stewart Chalmers

+1 818-681-3588

stewart.chalmers@bistel.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
  • DKT International Implements Traditional and New Forms of Marketing in Africa, South America, and Southeast Asia to Expand Access to Contraceptives
  • オルガノンが計画外妊娠をめぐり世界規模の対話の喚起を目指す
  • IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development
  • Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development